Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Hematologic Malignancies Testing Market Growth Analysis: How Will Revenue Expand During The Forecast Period?
The market for hematologic malignancy testing has experienced considerable expansion recently. Projections indicate a rise from $3.58 billion in 2025 to $4.06 billion by 2026, reflecting a compound annual growth rate of 13.4%. Factors fueling this past growth include a greater prevalence of blood cancers, the broader integration of molecular diagnostic techniques, the geographical spread of diagnostic testing facilities, increased utilization of complete blood count (CBC) and flow cytometry methods, and enhanced accessibility to cancer diagnostic services.
The hematologic malignancies testing market is poised for substantial acceleration in its expansion over the forthcoming years, projecting a market valuation of $6.68 billion by 2030, fueled by a compound annual growth rate of 13.2%. This projected ascent during the forecast period is largely propelled by a confluence of factors, including the escalating requirement for precision oncology diagnostics, the increasing incorporation of AI for data interpretation, the proliferation of companion diagnostics, a heightened reliance on MRD monitoring, and augmented investments in cutting-edge diagnostic technologies. Key developments anticipated within this timeframe encompass a greater embrace of NGS-based diagnostic testing, a surge in the utilization of flow cytometry for MRD detection, expanded integration of molecular and genetic assays, the broadening scope of personalized diagnostic profiling, and a more pronounced emphasis on achieving early and precise subtyping of these conditions.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24234&type=smp
Hematologic Malignancies Testing Market Growth Drivers: What Factors Are Accelerating Expansion?
The hematologic malignancies testing market is poised for expansion, driven by an increasing incidence of cancer diagnoses. Cancer diagnosis, which involves identifying the existence, nature, and extent of cancer through diverse medical assessments like scans, lab work, and biopsies, is seeing an uptick. This surge in diagnoses can be attributed to enhanced accessibility of screening initiatives and greater public consciousness, facilitating earlier identification. Hematologic malignancies testing plays a crucial role in this diagnostic process by allowing for the prompt detection, precise categorization, and tracking of blood cancers, which in turn informs tailored treatment strategies and enhances patient prognoses. For illustration, the American Cancer Society, a U.S. nonprofit, projects that in 2024, more than 2 million new cancer cases will be identified in the United States, representing a 4% rise compared to prior years. Consequently, the escalating count of cancer diagnoses serves as a key catalyst for the development of the hematologic malignancies testing sector.
Hematologic Malignancies Testing Market Segments: Where Are The Largest Growth Opportunities?
The hematologic malignancies testing market covered in this report is segmented –
1) By Test Type: Complete Blood Count (CBC), Flow Cytometry, Molecular Testing, Genetic Testing, Others Test Type
2) By Product: Kits, Services
3) By Technology: Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Immunohisto Chemistry (IHC), Cytogenetics, Others Technology
4) By Therapeutic Indication: Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others Therapeutic Indication
5) By End User: Hospitals, Diagnostic Labs, Academic and Research Institutions, Others End Users
Subsegments:
1) By Complete Blood Count (CBC): Hemoglobin Testing, Hematocrit Measurement, White Blood Cell Count, Red Blood Cell Count, Platelet Count, Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH)
2) By Flow Cytometry: Immunophenotyping, Cell Cycle Analysis, Apoptosis Detection, Minimal Residual Disease (MRD) Testing, DNA Content Analysis
3) By Molecular Testing: Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Reverse Transcriptase-PCR (RT-PCR), Fluorescence In Situ Hybridization (FISH), Microarray Analysis
4) By Genetic Testing: Germline Mutation Testing, Somatic Mutation Testing, Cytogenetic Testing, Chromosomal Aberration Detection, Single Nucleotide Polymorphism (SNP) Analysis
5) By Others Test Type: Bone Marrow Biopsy, Immunohistochemistry (IHC), Enzyme Assays, Serum Protein Electrophoresis (SPEP), Imaging Tests
Hematologic Malignancies Testing Market Trends: What Is Shaping Future Industry Growth?
The leading entities within the hematologic malignancies testing sector are concentrating their efforts on pioneering novel diagnostic methodologies, including swift molecular profiling. This strategic focus aims to equip healthcare practitioners with accurate and prompt diagnostic instruments, thereby facilitating earlier identification, refining treatment strategizing, and enabling more effective tracking of blood-related malignancies. Rapid molecular profiling represents a diagnostic strategy that scrutinizes an individual’s genetic constitution to pinpoint specific alterations and variations, paving the way for accelerated and highly tailored therapeutic choices. Illustratively, in November 2023, the Roswell Park Comprehensive Cancer Center, a prominent US-based institution, introduced PanHeme, an advanced gene sequencing instrument engineered to diagnose hematologic cancers like leukemia, lymphoma, and multiple myeloma with enhanced speed and accuracy. This particular testing method discerns mutations across numerous genes in less than three days, substantially boosting diagnostic efficiency and precision, ultimately informing more individualized treatment pathways for patients.
Hematologic Malignancies Testing Market Major Participants And Competitive Dynamics
Major companies operating in the hematologic malignancies testing market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Becton Dickinson and Company, Bio-Rad Laboratories Inc., Agilent Technologies Inc., Illumina Inc., Thermo Fisher Scientific Inc., Danaher Corporation, Sysmex Corporation, QIAGEN N.V., PerkinElmer Inc., Adaptive Biotechnologies Corporation, Invivoscribe Inc., ArcherDx Inc., Guardant Health Inc., Sophia Genetics SA, Natera Inc., Roche Diagnostics International AG, Laboratory Corporation of America Holdings
Access The Complete Hematologic Malignancies Testing Market Report:
Hematologic Malignancies Testing Market Regional Analysis: Which Region Leads By Revenue?
North Americawas the largest region in the hematologic malignancies testing market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the hematologic malignancies testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
